Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Portfolio Pulse from
Trevi Therapeutics has completed enrollment for its Phase 2a RIVER trial in refractory chronic cough and is halfway through enrollment for its Phase 2b CORAL trial in chronic cough related to idiopathic pulmonary fibrosis. The company ended Q3 2024 with $65.5 million in cash, providing a cash runway into the second half of 2026.
November 06, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Trevi Therapeutics completed enrollment for its Phase 2a RIVER trial and is progressing in its Phase 2b CORAL trial. The company has a strong cash position of $65.5 million, ensuring operations into the second half of 2026.
The completion of enrollment in the Phase 2a RIVER trial and progress in the Phase 2b CORAL trial are positive developments for Trevi Therapeutics, indicating advancement in their clinical pipeline. The strong cash position provides financial stability, which is crucial for ongoing and future trials. These factors are likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100